StockData
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aquestive Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.83+0.05 (+1.32%)

Close on Oct 19, 2026

Market cap
$478.73M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026After market close$13.80M$-0.18$-0.18
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026After market close$14.40M$-0.07–
Q4 FY2025
Ended Dec 31, 2025
Mar 4, 2026After market close$13.00M$-0.26$-0.15
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025After market close$12.80M$-0.14–
Q2 FY2025
Ended Jun 30, 2025
Aug 11, 2025After market close$10.00M$-0.14–
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025After market close$8.70M$-0.24–
Q4 FY2024
Ended Dec 31, 2024
Mar 5, 2025After market close$11.90M$-0.19–
Q3 FY2024
Ended Sep 30, 2024
Nov 4, 2024After market close$13.50M$-0.13–
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Mar 5, 2024After market close–––

Company guidance

Outlook given with results on Aug 11, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Non-GAAP adjusted EBITDA lossnon-GAAPfull-year 2026-$35.00M to -$30.00MMaintained
Total revenuefull-year 2026$46.00M to $50.00MMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Aquestive Therapeutics filed with the SEC